Nov 24 (Reuters) - Novartis Ag:
* REG-NOVARTIS TO ACQUIRE THE MEDICINES COMPANY FOR USD 9.7 BN, ADDING INCLISIRAN, A POTENTIALLY TRANSFORMATIONAL INVESTIGATIONAL CHOLESTEROL-LOWERING THERAPY TO ADDRESS LEADING GLOBAL CAUSE OF DEATH
* NOVARTIS - DEAL EXPECTED TO MODESTLY DILUTE CORE EPS VERSUS A NO DEAL SCENARIO DURING NEXT FEW YEARS AS CO INVESTS FOR A SUCCESSFUL LAUNCH OF INCLISIRAN
* TRANSACTION HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES
* NOVARTIS PLANS TO FINANCE TRANSACTION THROUGH AVAILABLE CASH AND SHORT- AND LONG-TERM BORROWINGS
* TRANSACTION IS EXPECTED TO CLOSE IN Q1 OF 2020, SUBJECT TO SATISFACTION OR WAIVER OF ALL CLOSING CONDITIONS
* NOVARTIS - EXPECTS DEAL TO BE SIGNIFICANTLY ACCRETIVE TO GROUP CORE OPERATING INCOME AND CORE EPS IN MEDIUM TERM
* ASSUMING COMPLETION IN Q1 OF 2020, CO EXPECTS INCLISIRAN TO START TO CONTRIBUTE TO GROUP AND IM DIVISION SALES FROM 2021 Source text for Eikon: Further company coverage:
